Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Dexchlorpheniramine. |
| Benzylpenicilloyl polylysine | Dexchlorpheniramine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent. |
| Betahistine | The therapeutic efficacy of Betahistine can be decreased when used in combination with Dexchlorpheniramine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Dexchlorpheniramine. |
| Mirabegron | The serum concentration of Dexchlorpheniramine can be increased when it is combined with Mirabegron. |
| Amphetamine | Amphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Phentermine | Phentermine may decrease the sedative activities of Dexchlorpheniramine. |
| Pseudoephedrine | Pseudoephedrine may decrease the sedative activities of Dexchlorpheniramine. |
| Benzphetamine | Benzphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Diethylpropion | Diethylpropion may decrease the sedative activities of Dexchlorpheniramine. |
| Lisdexamfetamine | The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Dexchlorpheniramine. |
| Mephentermine | Mephentermine may decrease the sedative activities of Dexchlorpheniramine. |
| MMDA | MMDA may decrease the sedative activities of Dexchlorpheniramine. |
| Midomafetamine | Midomafetamine may decrease the sedative activities of Dexchlorpheniramine. |
| 2,5-Dimethoxy-4-ethylamphetamine | 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| 4-Bromo-2,5-dimethoxyamphetamine | 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Tenamfetamine | Tenamfetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Chlorphentermine | Chlorphentermine may decrease the sedative activities of Dexchlorpheniramine. |
| Methylenedioxyethamphetamine | Methylenedioxyethamphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Dextroamphetamine | Dextroamphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Metamfetamine | Metamfetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Iofetamine I-123 | Iofetamine I-123 may decrease the sedative activities of Dexchlorpheniramine. |
| Ritobegron | Ritobegron may decrease the sedative activities of Dexchlorpheniramine. |
| Mephedrone | Mephedrone may decrease the sedative activities of Dexchlorpheniramine. |
| Methoxyphenamine | Methoxyphenamine may decrease the sedative activities of Dexchlorpheniramine. |
| Gepefrine | Gepefrine may decrease the sedative activities of Dexchlorpheniramine. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Dexchlorpheniramine. |
| Phendimetrazine | Phendimetrazine may decrease the sedative activities of Dexchlorpheniramine. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Dofetilide. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Citalopram. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Anagrelide. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Disopyramide. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Clemastine. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Ibutilide. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Valproic acid. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Grepafloxacin. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Toremifene. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Cisapride. |
| Imatinib | The serum concentration of Dexchlorpheniramine can be increased when it is combined with Imatinib. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Thioridazine. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Trovafloxacin. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Mifepristone. |
| Cocaine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Cocaine. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Quinidine. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Arsenic trioxide. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Domperidone. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Sparfloxacin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Halofantrine. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Bepridil. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Paliperidone. |
| Lithium cation | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Lithium cation. |
| Temafloxacin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Temafloxacin. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Zuclopenthixol. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Tetrabenazine. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Iloperidone. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Vandetanib. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Romidepsin. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Asenapine. |
| Artemether | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Artemether. |
| Vemurafenib | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Vemurafenib. |
| Eliglustat | The metabolism of Dexchlorpheniramine can be decreased when combined with Eliglustat. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Dexchlorpheniramine. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Glasdegib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Deutetrabenazine. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Macimorelin. |
| Terodiline | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Terodiline. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Amiodarone. |
| Nilotinib | The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Nilotinib. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Dexchlorpheniramine. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Dexchlorpheniramine. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dexchlorpheniramine. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Dexchlorpheniramine. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Dexchlorpheniramine. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Dexchlorpheniramine. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Dexchlorpheniramine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Dexchlorpheniramine. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Dexchlorpheniramine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Dexchlorpheniramine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Dexchlorpheniramine. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Dexchlorpheniramine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Dexchlorpheniramine. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Dexchlorpheniramine. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Dexchlorpheniramine. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Dexchlorpheniramine. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Dexchlorpheniramine. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Dexchlorpheniramine. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Dexchlorpheniramine. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Dexchlorpheniramine. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Dexchlorpheniramine. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Dexchlorpheniramine. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Dexchlorpheniramine. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Dexchlorpheniramine. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Dexchlorpheniramine. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Dexchlorpheniramine. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Dexchlorpheniramine. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Dexchlorpheniramine. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Dexchlorpheniramine. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Dexchlorpheniramine. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Dexchlorpheniramine. |